24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Actavis
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
10:47
“We never stopped investing in our talent”: Salesforce doubles down on junior hiring
10:39
Denmark picks Covenant’s Anthem missile in first long-range strike purchase
08:32
Your cybersecurity pricing model is now an attack surface
22:51
Did Datadog really offer $4 billion for Israeli cyber startup Upwind?
More stories
Buzz
Most popular
Daily
Weekly
1
Did Datadog really offer $4 billion for Israeli cyber startup Upwind?
2
Qualcomm lays out layoffs after annual reviews, citing employees who “fell short”
3
Israel’s Elbit to supply Azerbaijan with $235 million in rockets and launchers
4
Bill Ackman in Israel: "The country could become one of the best economies in the world"
5
Secretive Israeli AI startup raises tens of millions backed by Bill Ackman and Eric Schmidt
More news
Actavis
5 stories about Actavis
Allergan Says Teva Bears Sole Liability for Actavis' Actions
02.09.19
|
Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
The Crucial Piece of Information Teva Overlooked
24.12.17
|
Sophie Shulman
When Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.
Teva Wants to Be Like Mylan: Agile, Lean and Profitable
17.12.17
|
Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
Allergan Sketches Road Show to Sell Teva Stake
14.08.17
|
Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
Allergan Can Now Sell 9.8% Teva Stake
03.08.17
|
Dror Reich
Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended